Drugs / endothelial progenitor cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04187625 | Jan 2023 → Jan 2024 | kidney disorder | Brigham and Women's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | endothelial progenitor cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04187625 ↗ |
| Modality | Cell therapy | “Cell-based Therapy for the Treatment of Kidney Disease” NCT04187625 ↗ |
| Route | Other | “delivered percutaneously to the kidney blood supply.” NCT04187625 ↗ |